Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):823-33.

View in: PubMed

subject areas

Adenoviridae
Adolescent
Adult
Aged
Antiviral Agents
Brain Neoplasms
Combined Modality Therapy
Female
Follow-Up Studies
Ganciclovir
Genetic Therapy
Glioma
Humans
Male
Middle Aged
Neoplasm Grading
Prognosis
Survival Rate
Thymidine Kinase
Young Adult

authors with profiles

Peter Christian Warnke